Abstract
Preliminary studies using anti-KIT antibodies (Huang et al. 2008), anti-TNF-α antibodies (Gounaris et al. 2007) or the MC stabilizer disodium cromoglycate (cromolyn) (Soucek et al. 2007) in mouse models demonstrated promising results even if administered after the initiation of tumour development. Treatment of mice bearing mammary adenocarinoma and pancreatic cancer with cromolyn led to clotting of blood vessels, hypoxia and tumour cell apoptosis (Samoszuk and Corwin 2003a, b; Soucek et al. 2007). Unfortunately, cromolyn is a weak inhibitor of human MC secretion and is poorly adsorbed, so it is unlikely to be effective in treating cancer in humans.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Ribatti, D., Crivellato, E. (2011). Drugs Affecting Mast Cells. In: Mast Cells and Tumours. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-1469-4_9
Download citation
DOI: https://doi.org/10.1007/978-94-007-1469-4_9
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-1468-7
Online ISBN: 978-94-007-1469-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)